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RESEARCH ARTICLE
Ankylosing spondylitis patients at risk of poor
radiographic outcome show diminishing
spinal radiographic progression during long-
term treatment with TNF-α inhibitors
Fiona Maas1*, Suzanne Arends1,2, Freke R. Wink2, Reinhard Bos2, Hendrika Bootsma1,
Elisabeth Brouwer1, Anneke Spoorenberg1,2
1 Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen,




To investigate the influence of patient characteristics on the course of spinal radiographic
progression in a large prospective longitudinal cohort study of ankylosing spondylitis (AS)
patients treated long-term with TNF-α inhibitors.
Methods
Consecutive patients from the Groningen Leeuwarden AS (GLAS) cohort starting TNF-α
inhibitors with spinal radiographs at least available at baseline and 6 years of follow-up were
included. Radiographs were scored using mSASSS by two independent readers. General-
ized estimating equations (GEE) were used to explore the associations between baseline
characteristics and spinal radiographic progression. The course of radiographic progression
in patients with and without risk factors for poor radiographic outcome was investigated
using different time models (linear and non-linear). Single linear imputation was used in
case of missing radiographic data at the intermediate (2 or 4 years) follow-up visits.
Results
80 AS patients were included with mean baseline mSASSS 8.7±13.3. Baseline syndesmo-
phytes, male gender, older age, longer symptom duration, smoking, and higher BMI were
significantly associated with more radiographic damage over time. GEE analysis in patients
with these risk factors revealed that radiographic progression followed a non-linear course
with mean mSASSS progression rates reducing from max. 2.8 units over 0–2 years to min.
0.9 units over 4–6 years. The GEE model revealed a linear course with overall very low pro-
gression (1 mSASSS units/2yrs) in patients without risk factors. Complete case analysis in
53 patients showed similar results.
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Conclusion
AS patients at risk of poor radiographic outcome showed the highest but diminishing spinal
radiographic progression during long-term treatment with TNF-α inhibitors.
Introduction
In view of the clinical evaluation of new potential biological therapies in axial spondyloarthritis
(axSpA) including ankylosing spondylitis (AS), it is important to identify which patients are
at risk for radiographic progression. In earlier studies, spinal radiographic progression was
found to be associated with the presence of baseline syndesmophytes, male gender, older age,
smoking, worse functional status, and higher disease activity at baseline.[1–7] Among these
risk factors, the presence of baseline syndesmophytes is the strongest predictor.[5,6,8] In our
previous analysis of 176 AS patients long-term treated with tumor necrosis factor-alpha (TNF-
α) inhibitors, patients with baseline syndesmophytes showed a 4-fold higher progression rate
than patients without syndesmophytes.[4] Furthermore, elevated C-reactive protein (CRP)
was identified as a strong predictor (OR 4.7 in multivariable model) for the progression of
non-radiographic axSpA to AS based on the modified New York criteria.[9]
In addition to baseline risk factors, previous cohort studies in axSpA patients, mainly
treated with non-steroidal anti-inflammatory drugs (NSAIDs), have demonstrated that spinal
radiographic progression is associated with disease activity over time.[10,11] In the German
Spondyloarthritis Inception Cohort (GESPIC), mean AS disease activity scale (ASDAS), eryth-
rocyte sedimentation rate (ESR), and CRP over 2 years were significantly associated with spi-
nal radiographic progression during these 2 years.[10] In the historical Outcomes in AS
International Study (OASIS), a longitudinal relationship was found between spinal radio-
graphic progression and assessments of disease activity over a follow-up period up to 12 years.
Bath AS disease activity index (BASDAI), ASDAS, and CRP at the start of a 2-year time inter-
val were significantly associated with radiographic progression during the next 2 years.[11]
Based on the multiple reported associations between disease activity over time and radio-
graphic progression, we hypothesized that prolonged inhibition of disease activity could
eventually lead to less spinal radiographic progression over time. In our recent study using lon-
gitudinal modeling of spinal radiographic progression in AS patients treated with TNF-α
inhibitors, a deflection from a linear course with significantly decreasing progression rates was
found at the group level after more than 4 years of follow-up (estimated mean progression
rates reduced from 1.7 over 0–2 years to 1.0 over 4–6 years).[12]. Since individual progression
rates were highly variable, it is important to explore the course of radiographic progression at
individual patient level and to identify patient characteristics associated with this reduction in
spinal radiographic progression. Therefore, the aim of the present study was to investigate the
influence of patient characteristics on the course of spinal radiographic progression in AS
patients treated long-term with TNF-α inhibitors.
Methods
For the present study, we included consecutive outpatients from the Groningen Leeuwarden
AS (GLAS) cohort who started treatment with TNF-α inhibitors between 2004 and 2009 and
had spinal radiographs available at baseline and after 6 years of follow-up. Patient selection cri-
teria and details about the study design have been described previously.[12] The GLAS cohort
Patient characteristics and radiographic progression in AS
PLOS ONE | https://doi.org/10.1371/journal.pone.0177231 June 22, 2017 2 / 12
required prior to access. Data requests can be sent
to Research Data Office University of Groningen:
researchdata@rug.nl.
Funding: The GLAS cohort was supported by an
unrestricted grant from Pfizer. Pfizer had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: F. Maas: None declared; S.
Arends: Grant/research support from Pfizer; F.R.
Wink consultant for Abbvie; R. Bos: None declared;
H. Bootsma: None declared; E. Brouwer: Grant/
research support from Pfizer; A. Spoorenberg:
Grant/research support from Abbvie, Pfizer, UCB,
consultant for Abbvie, Pfizer, MSD, UCB, and
Novartis. This does not alter our adherence to
PLOS ONE policies on sharing data and materials.
is a Dutch ongoing prospective longitudinal observational cohort study with a standardized
assessment and management protocol. Included patients were 18 years or older, fulfilled the
modified New York criteria for AS, and the ASAS criteria to start TNF-α inhibitors.[13] The
GLAS cohort was approved by the local ethics committees of the Medical Center Leeuwarden
(MCL) and the University Medical Center Groningen (UMCG). All patients provided written
informed consent according to the Declaration of Helsinki.
Patient characteristics
The following baseline characteristics were collected: gender, age, symptom duration, time
since diagnosis, HLA-B27 status, body mass index (BMI), smoking status (no/previous smoker
vs. current smoker), smoking duration (of current and previous smokers), use of NSAIDs
(yes/no), use of disease-modifying antirheumatic drugs (DMARDs, yes/no), first TNF-α inhib-
itor (etanercept vs. infliximab/adalimumab), BASDAI, ASDAS, patient’s global assessment of
disease activity (GDA), CRP level, and Bath AS functional index (BASFI).
Radiological assessment
Radiographs of the cervical and lumbar spine were scored in chronological time order by two
trained readers (FM and IE) using the modified Stoke AS spine score (mSASSS).[14,15] Radio-
graphs were randomized and scored together with radiographs of AS patients who were not
treated with TNF-α inhibitors from a historical cohort in order to avoid potential reader bias
concerning the applied therapy. Patient characteristics were removed from the radiographs.
Further details about the scoring method including inter-observer reliability have been
described previously.[12]
Statistical analysis
Spinal radiographic progression was evaluated using generalized estimating equations (GEE).
GEE is a statistical technique used to investigate longitudinal relationships between variables.
The advantage of GEE is that all available data at different time points (0, 2, 4, 6 year) are
included in the model. GEE can correct for the fact that measurements over different time
points are highly correlated within patients. In the present study, an exchangeable correlation
structure was used.[3,4,12]
First, univariable GEE were used to explore the associations between patient characteristics
at baseline and spinal radiographic damage over time. Multivariable GEE was used to identify
the independent risk factors for radiographic progression.
Second, the course of spinal radiographic progression was investigated after stratifying the
patients with and without risk factors for poor radiographic outcome. In case continuous vari-
ables were significantly associated with radiographic damage over time, stratification into sub-
groups was based on clinically relevant values or medians. In these subgroups, the course of
spinal radiographic damage over time was investigated using linear and different non-linear
time models (quadratic, cubic, square root, logarithmic, exponential); mSASSS was the inde-
pendent variable and time the dependent variable. The time model with a significant contribu-
tion (p-value0.05) and the lowest quasi-likelihood information criterion (QICC) represents
the best model for the data. The mean mSASSS status scores at baseline and 2, 4 and 6 years
and the mean 2-year progression rates were calculated based on the estimated intercept and
regression coefficients obtained from this model.
The analyses were performed in patients with radiographic data available at baseline and
after 6 years of follow-up. In case a patient had missing data at one or more intermediate fol-
low-up visits (2 or 4 year), missing radiographic data was imputed using a single linear
Patient characteristics and radiographic progression in AS
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imputation technique. With this technique, an ongoing linear progression was assumed during
the imputed time interval.[12] Additionally, complete case analysis was performed in patients
with complete radiographic data at all 2-year time points. Statistical analysis was performed
with IBM SPSS Statistics 22 (SPSS, Chicago, IL, USA).
Results
In total, 98 AS patients from the GLAS cohort had 6 years of follow-up of which 80 had radio-
graphic data available at baseline and at 6 years. These 80 patients had similar patient charac-
teristics as the 18 patients without radiographic data (data not shown). Complete biannual
radiographic data at all the intermediate time points (0, 2, 4, 6 years) were available for 53
(66%) patients. Baseline characteristics did not significantly differ between patients with and
without complete radiographic data, except for the distribution of first prescribed TNF-α
agent (S1 Table).
Almost all patients had high disease activity at baseline and stable, low disease activity over
time after the start of TNF-α inhibitors (S1 Fig).
Of the 80 included patients, most started treatment with etanercept (n = 50), followed by
both infliximab (n = 15) and adalimumab (n = 15). Fifty-five (69%) patients continued using
their first TNF-α agent and 23 (29%) patients switched to another TNF-α agent during follow-
up. Only 2 (2%) patients stopped TNF-α inhibition because of inefficacy. The mean duration
of TNF-α inhibition was 5.4±1.2 years.
Included patients had a median mSASSS at baseline of 3.3 (IQR: 0.0–12.0), a mean mSASSS
of 8.7±13.3, and 43 (54%) patients had one or more non-bridging or bridging syndesmophytes
(Table 1).
Patient characteristics associated with radiographic damage over time
Male gender, age, symptom duration, BMI, and baseline damage were significantly associated
with spinal radiographic damage over time (Table 2). Similar result were found for patients
using etanercept vs. infliximab or adalimumab. Multivariable GEE revealed that the presence
of baseline syndesmophytes was the only independent predictor for radiographic progression.
Complete case analysis in 53 AS patients with radiographic data available at all 2-year time
points revealed similar results. Additionally, time since diagnosis and current smoking status
reached statistical significance (p<0.05, S2 Table).
Radiographic progression in patients with risk factors
Patients with baseline syndesmophytes, male gender, age40 years, symptom duration10
years, and BMI25kg/m2 had higher baseline mSASSS and higher progression rates than
patients without these characteristics (Table 3). Longitudinal modeling stratified for presence
of these patient characteristics revealed that the course of spinal radiographic progression was
non-linear with reducing progression rates over time (Table 3, Fig 1). The mean estimated
progression rates reduced from maximal 2.8 mSASSS units over 0–2 years to minimal 0.9
mSASSS units over 4–6 years. The strongest deflection from a linear course was found in
patients with baseline syndesmophytes and in patients with baseline BMI25kg/m2 (Table 3).
The majority (>65%) of patients with syndesmophytes at baseline had one or more other
risk factors, e.g. male gender, age40 years, symptom duration10 years, and/or BMI
25kg/m2. A second risk factor in addition to the presence of syndesmophytes resulted in an
additional increase in the progression rate of 0.2–0.4 mSASSS units during the first 2 years of
follow-up (Table 4). Overall, progression rates reduced from maximal 3.2 mSASSS units over
Patient characteristics and radiographic progression in AS
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0–2 years to minimal 1.2 mSASSS units over 4–6 years in patients with multiple risk factors
(Table 4).
Complete case analysis in 53 AS patients with radiographic data available at all 2-year time
points revealed similar results. An additional finding was that patients with a time since diag-
nosis of5 years and current smokers also showed high but reducing progression rates over
time (S3 Table).
Radiographic progression in patients without risk factors
Patients without baseline syndesmophytes, female patients, patients age<40 years, symptom
duration <10 years, and BMI<25kg/m2 showed less spinal damage at baseline (Table 3). Lon-
gitudinal modeling in these patients revealed that the course of spinal radiographic progres-
sion was linear with low estimated progression rates of1 mSASSS units per 2 years. The
lowest progression rates were found in patients without baseline syndesmophytes (Table 3,
Fig 1).
Table 1. Baseline characteristics of included AS patients.
Total group
n = 80
Male gender 56 (70)
Age (yrs) 41.3 ± 10.5
Symptom duration (yrs) 14 (8–24)
Time since diagnosis (yrs) 5 (1–15)
HLA-B27+ 62 (78)
BMI (kg/m2) 25.6 ± 3.8
Current smoker 28 (42)
Smoking duration (yrs) 13 (0–26)
NSAID use 69 (86)
ASAS-NSAID index 50 (25–100)





BASDAI (0–10) 6.0 ± 1.7
ASDASCRP 3.8 ± 0.8
Patient’s GDA (0–10) 7 (5–8)
CRP (mg/L) 14 (7–23)
ESR (mm/hr) 21 (13–34)
BASFI (0–10) 5.6 (3.6–7.1)
mSASSS (range 0–72) mean 8.7 ± 13.3
median 3.3 (0.0–12.0)
1 syndesmophyte 43 (54)
Values are presented as number of patients (%), mean ± SD, or median (IQR).
AS: ankylosing spondylitis; HLA: human leukocyte antigen; BMI: body mass index; NSAID: non-steroidal
anti-inflammatory drug; ASAS: Assessment of SpondyloArthritis international Society; DMARD: disease-
modifying anti-rheumatic drug; BASDAI: Bath AS disease activity index; ASDAS: AS disease activity score;
GDA: global disease activity; BASFI: Bath AS functional index; CRP: C-reactive protein; mSASSS: modified
Stoke AS spine score.
https://doi.org/10.1371/journal.pone.0177231.t001
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Complete case analysis in 53 AS patients with radiographic data available at all 2-year time
points revealed similar results (S3 Table).
Discussion
In the present analysis, we evaluated the influence of patient characteristics on the long-term
course of spinal radiographic progression in AS patients receiving prolonged TNF-α inhibitors
in daily clinical practice. A small decrease in mSASSS progression rates during 6 years of follow
up was observed in patients with risk factors for poor radiographic outcome, including the
most important and well-known risk factor; baseline syndesmophytes. Furthermore, slow and
linear progression was observed in patients without risk factors for poor radiographic outcome.
The decreasing progression rates might be a result of the stable low disease activity in patients
receiving TNF-α inhibitors for a long period of time. In patients with baseline syndesmophytes,
the 2-year progression rate nearly halved during the last 2-years of follow-up (4–6 years) as com-
pared to the first 2 years of follow-up (0–2 years). Reducing progression rates were also found in
male patients, patients with older age, longer symptom duration, and higher BMI. Very low and
stable progression rates of1 mSASSS units per 2 years were found in patients without these
risk factors. A recent prospective longitudinal cohort study in 334 AS patients found that
patients starting TNF-α inhibitors more than 10 years from start of symptoms had an increased
risk (OR: 2.4) for radiographic progression compared to patients with a shorter delay, after cor-
recting for baseline syndesmophytes. The authors indicated that the effect of TNF-α inhibitors
Table 2. Associations between baseline characteristics and spinal radiographic damage over time.
Total group (n = 80)
B (95% CI) p-value
Male gender 8.87 (3.37–14.38) 0.002
Age (yrs) 0.70 (0.41–0.98) <0.001
Age40 years 9.49 (3.53–15.45) 0.002
Symptom duration (yrs) 0.74 (0.36–1.11) <0.001
Symptom10 years 12.29 (7.50–17.07) <0.001
Time since diagnosis (yrs) 0.50 (-0.01–1.01) 0.056
HLA-B27+ 0.23 (-7.37–7.82) 0.953
Current smoker 6.16 (-0.05–12.82) 0.070
Smoking duration 0.28 (-0.03–0.58) 0.072
BMI (kg/m2) 1.53 (0.41–2.64) 0.007
BMI25 kg/m2 12.62 (4.85–20.40) 0.001
NSAID use 4.17 (3.30–11.63) 0.274
DMARD use -2.38 (-9.70–4.95) 0.525
First TNF-α inhibitor† -2.70 (-9.65–4.26) 0.447
BASDAI (0–10) -0.59 (-2.17–0.98) 0.461
ASDASCRP 1.91 (-2.30–6.11) 0.375
Patient’s GDA (0–10) -0.33 (-1.59–0.94) 0.610
CRP (mg/L) 0.08 (-0.14–0.30) 0.456
BASFI (0–10) 0.85 (-0.44–2.14) 0.197
mSASSS 1.11 (1.05–1.17) <0.001
1 syndesmophyte 18.33 (13.57–23.10) <0.001
See Table 1 for abbreviations.
†Etanercept vs. infliximab/adalimumab
https://doi.org/10.1371/journal.pone.0177231.t002
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Table 3. GEE estimated mean 2-year spinal radiographic progression rates, stratified for baseline risk factors.







Total group 80 Non-linear 1.7 (1.1–2.3) 1.5 (0.8–2.3) 1.0 (-0.1–2.1)
Syndesmophytes Yes 43 Non-linear 2.8 (1.9–3.7) 2.5 (1.3–3.6) 1.6 (-0.1–3.3)
No 37 Linear 0.4 (0.2–0.7) 0.4 (0.2–0.7) 0.4 (0.2–0.7)
Gender Male 56 Non-linear 2.1 (1.3–2.8) 1.9 (0.9–2.8) 1.3 (-0.1–2.7)
Female 24 Linear 0.7 (0.3–1.2) 0.7 (0.3–1.2) 0.7 (0.3–1.2)
Age 40 years 43 Non-linear 2.3 (1.4–3.2) 2.0 (0.9–3.2) 1.3 (-0.4–3.0)
<40 years 37 Linear 0.9 (0.5–1.4) 0.9 (0.5–1.4) 0.9 (0.5–1.4)
Symptom duration 10 years 52 Non-linear 2.3 (1.4–3.1) 2.0 (0.9–3.0) 1.3 (-0.4–2.8)
<10 years 25 Linear 0.6 (0.2–1.0) 0.6 (0.2–1.0) 0.6 (0.2–1.0)
BMI 25 kg/m2 26 Non-linear 2.5 (1.4–3.8) 2.1 (1.0–3.6) 0.9 (0.0–3.1)
<25 kg/m2 22 Linear 0.9 (0.3–1.5) 0.9 (0.3–1.5) 0.9 (0.3–1.5)
Values are presented as mean (95% CI).
mSASSS: modified Stoke AS Spine Score; BMI: body mass index.
https://doi.org/10.1371/journal.pone.0177231.t003
Fig 1. GEE estimated course of spinal radiographic progression in AS patients with 6 years of follow-up (n = 80), stratified
for baseline risk factor.
https://doi.org/10.1371/journal.pone.0177231.g001
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on radiographic progression is most pronounced at an early stage of the disease, before struc-
tural damage is present.[7] The reducing progression rates in AS patients with more longstand-
ing and advanced disease, as shown in the present study, suggest that TNF-α inhibitors may also
influence spinal radiographic progression at a later stage of the disease.
Associations between radiographic progression and clinical disease activity, inflammatory
markers, physical functioning, and NSAID use, as found in previous studies [5–7,10,16],
could not be demonstrated in the present study. At least, variation in disease activity between
patients over time is needed to show any possible association between disease activity and spi-
nal radiographic progression.[11] Almost all patients had high disease activity at baseline and
stable, low disease activity over time due to the effect of TNF-α inhibitors. As a consequence,
no inter-patient variation of disease activity was present which explains that no significant
association between disease activity and spinal radiographic progression could be found. The
same explanation can be applied for the lack of association between NSAIDs and spinal radio-
graphic progression in our study, since the use of NSAIDs was also high at baseline and
decreased rapidly after starting TNF-α inhibitors. No differences in radiographic outcome
were found in patients treated with the receptor antagonist (etanercept) and monoclonal anti-
bodies (infliximab and adalimumab). However, these results should be taken with caution due
to small numbers and the possibility of selection bias.
It is well-known that a healthy lifestyle is important to enhance an overall general health.
Obesity and smoking are related to comorbidities, e.g. cardio-vascular diseases, diabetes, dif-
ferent forms of cancer, and increased mortality.[17,18] In the present study, we demonstrated
that BMI is associated with worse radiographic outcome in AS. Overweight and obese patients
(BMI25kg/m2) had higher radiographic damage at baseline and an increased risk for devel-
oping radiographic damage over time. A comparable association has been found in a retro-
spective study in 47 AS patients with unknown follow-up duration.[19] Although BMI was not
an independent risk factor, it may have a contributory role in the development of new bone in
AS. In a SpA mouse model, new bone formation was associated with biomechanical stress at
the entheseal sites and inflammation.[20] Increased body weight results in increased bio-
mechanical stress. In addition, previous studies have found that BMI is associated with higher
disease activity, including elevated CRP levels.[21,22] Less effect of TNF-α inhibitors on dis-
ease activity and physical functioning has been found in obese or overweight axSpA and AS
patients.[23,24] Additional analysis in the present study also showed higher disease activity
over time in patients with overweight or obesity (data not shown).
In addition to higher BMI, current smoking status was significantly associated with worse
radiographic outcome in complete case analysis. This risk factor has also been reported in pre-
vious studies in AS and axial SpA.[6,7] From literature, it is known that smoking is associated
Table 4. GEE estimated mean 2-year spinal radiographic progression rates over time of AS patients with multiple risk factors.







Syndesmophytes 43 Non-linear 2.8 (1.9–3.7) 2.5 (1.3–3.6) 1.6 (-0.1–3.3)
Syndesmophytes & male gender 35 Non-linear 3.0 (1.9–4.0) 2.7 (1.3–4.0) 1.8 (-0.2–3.9)
Syndesmophytes & age40 years 31 Non-linear 3.0 (1.8–4.1) 2.6 (1.2–4.1) 1.6 (-0.6–4.1)
Syndesmophytes & symptom duration10 years 35 Non-linear 3.1 (2.0–4.1) 2.7 (1.4–4.0) 1.6 (-0.4–3.6)
Syndesmophytes & BMI25 kg/m2 19 Non-linear 3.2 (1.6–4.8) 2.6 (0.8–4.5) 1.2 (-1.6–3.9)
Values are presented as mean (95% CI). See Table 1 for abbreviations.
https://doi.org/10.1371/journal.pone.0177231.t004
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with functional impairment, higher disease activity and more inflammation on MRI.[25,26]
An observational cohort study in 1576 Danish AS patient showed that current and previous
smokers had worse treatment response to TNF-α inhibitors than never smokers.[27] Compo-
nents of tobacco smoke can activate immune responses leading to higher secretion of pro-
inflammatory cytokines. More inflammation and functional impairment may result in more
new bone formation.[6] Therefore, lifestyle coping such as weight reduction and smoking ces-
sation should be taken into account during the management of AS.
During the analyses of long-term prospective data, losses to follow-up and incomplete fol-
low-up data should be taken into account. The number of drop-outs in our cohort over 6 years
of follow-up was rather low (12%) but we had to deal with missing data at intermediate follow-
up visits (15% of all visits). We resolved this by using a single linear imputation technique in
which a linear course was assumed during the imputed time intervals. Importantly, baseline
characteristics were comparable between patients with complete and incomplete radiographic
data. Complete case analysis revealed similar results as the analyses in the total group.
The mean estimated progression rates as presented in this study were derived from the
GEE model with the best fit for the data. Significant contribution and goodness-of-fit of differ-
ent time models were explored in order to investigate whether spinal radiographic progression
followed a linear or non-linear course. Similar methodology has previously been used in the
OASIS cohort and in our previous study to investigate the course of spinal radiographic pro-
gression and longitudinal relationships between variables.[3,4] Some caution is needed during
the interpretation of the results in the small subgroups, such as the BMI groups in complete
case analysis. Unfortunately, the measurement error of the mSASSS is relatively large, as was
also demonstrated in other studies.[3] In our study the smallest detectable change was 2.3 for
scoring 2-year mSASSS progression. This indicates that, on average, most patients and espe-
cially the patients without risk factors showed progression rates within the measurement
error. Therefore, it is difficult to interpret whether these patients showed ‘real’ progression or
whether the observed progression rate was caused by the measurement error.
In conclusion, the present study was the first that investigated the influence of important
patient characteristics on the course of spinal radiographic progression in AS patients during
long-term treatment with TNF-α inhibitors. AS patients at risk of developing radiographic
damage showed a deflection from a linear course with reducing progression rates over time.
The strongest deflection was found in patients with multiple risk factors, the presence of base-
line syndesmophytes was the most important. In contrast, linear and very low progression
rates, even smaller than measurement error, were observed in patients without risk factors,
including patients without baseline syndesmophytes, female patients, non-smokers, and
patients at younger age, with shorter disease duration, and normal BMI.
The data presented in this study are of great clinical importance since knowledge about the
course of spinal radiographic progression in different patient groups will influence treatment
decisions in daily clinical practice of AS. In addition, our results emphasize that clinicians and
patients should be aware of the possible negative consequences of poor lifestyle factors such as
overweight/obesity and smoking on radiographic outcome. Future studies conducted in well-
organized large prospective cohorts with standardized follow-up visits are needed to confirm
our results.
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